Anti-inflammatory effects of the macrolides

Journal of Otolaryngology

Volumn 31, Issue SUPPL. 1, 2002, Pages

  Davidson, Ross ^a   Péloquin, Louis ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antibiotics; Immunomodulation; Inflammation; Macrolides

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYTOKINE; MACROLIDE;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; IMMUNOMODULATION; MUCOCILIARY CLEARANCE; PRIORITY JOURNAL; RESPIRATORY BURST; SHORT SURVEY;

EID: 0036696485     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2002.21285     Document Type: Short Survey

References (26)

1. Mandell LA, Marrie TJ, Grossman RF, et al., and the Canadian CAP Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update. Clin Infect Dis 2000; 31:383-421.
2. Itkin IH, Menzel ML, Denver C. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970; 45:146-162.
3. Kamada AK, Hill MR, Ikle DN, et al. Efficacy and safety of low concentration troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993; 91:873-882.
4. Miyatake H, Taki F, Taniguchi H, et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991; 99:670-673.
5. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990; 141:72-87.
6. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin, and clarithromycin. J Antimicrob Chemother 1998; 41(Suppl):47-50.
7. Nelson S, Summer WR, Terry PB. Erythromycin induced suppression of pulmonary antibacterial defenses. A potent mechanism of superinfection in the lung. Am Rev Respir Dis 1987; 136:1207-1212.
8. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155:2018-2023.
9. Rhee CS, Majima Y, Arima S, et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000; 169:484-487.
10. Mura S, Ishiara SH, Satoh M. Endothelin regulation of mucus glycoprotein secretion from feline tracheal submucosal glands. Am J Physiol 1992; 262:208-213.
11. Sirois MG, Filep JG, Rouseau A. Endothelin-1 enhances vascular permeability in conscious rats: role of thromboxane A2. Eur J Pharmacol 1992; 214:119-125.
12. Vittori I, Marini M, Fasoli A. Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids. Am Rev Respir Dis 1992; 146:1320-1325.
13. Lambro MT, El Brenna J, Babin-Chevaye C. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989; 24:561-572.
14. Hand WL, Hand D, King-Thompson N. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1990; 34:863-870.
15. Khair OA, Devalia JL, Abdelaziz MM. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of II-6, II-8, and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8:1451-1457.
16. Kawasaki S, Takizawa H, Takayuki O. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in-vitro. Antimicrob Agents Chemother 1998; 42:1499-1502.
17. Schultz M, Speelman P, Zaat S. Erythomycin inhibits tumour necrosis factor alpha killed and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 1998; 42:1605-1609.
18. Miyanohara T, Ushikai M, Matsune S, et al. Effects of clarithromycin on cultured human epithelial cells and fibroblasts. Laryngoscope 2000; 110:126-131.
19. MacLeod CM, Hamid QA, Cameron L, et al. Anti-inflammatory activity of clarithromycin in the treatment of adults with chronically inflamed sinus mucosa. Adv Ther 2001; 18:75-82.
20. Tremblay C, MacLeod CM, Brisco W. Improvement of clinical signs and symptoms of chronic inflammatory sinusitis with clarithromycin [abstract]. European Congress of Chemotherapy, Madrid, May 2000.
21. Rosenberg SM, Gerhand H, Grunstein MM. Use of TAO without methylprednisolone in the treatment of severe asthma. Chest 1991; 100:849-850.
22. Kadota J, Sakito O, Kohno S. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147:153-159.
23. Kobayashi H. Biofilm disease: its clinical manifestations and therapeutic possibilities of macrolides. Am J Med 1995; 99(Suppl 6A):26-30.
24. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 1997; 40:153-155.
25. Tsang KWT, Ho PI, Chan KN. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13:361-364.
26. Gurfinkel E, Bozovich G, Daroca A. Randomized trial of roxithromycin in non-Q-wave coronary syndromes. Lancet 1997; 350:404-407.